Oteseconazole

Summary

Oteseconazole (CHEMBL3311228) is an approved small molecule (ATC J02AC06); indicated across 4 conditions including vulvovaginal candidiasis and tinea pedis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J02AC06
• Indications: 4 conditions
• Clinical trials: 6
• Chemistry: 527.4 Da · C23H16F7N5O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3311228
Name	Oteseconazole
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	77050711
ATC	J02AC06
Molecular formula	C23H16F7N5O2
Molecular weight	527.4
InChIKey	IDUYJRXRDSPPRC-NRFANRHFSA-N

SMILES: C1=CC(=CC=C1C2=CN=C(C=C2)C([C@](CN3C=NN=N3)(C4=C(C=C(C=C4)F)F)O)(F)F)OCC(F)(F)F

IUPAC name: (2R)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(tetrazol-1-yl)-1-[5-[4-(2,2,2-trifluoroethoxy)phenyl]-2-pyridinyl]propan-2-ol

Also known as: Oteseconazol, Oteseconazole, Vivjoa, Vt-1161, VT-1161, OTESECONAZOLE, C0088428

Patent coverage: 82 distinct patent families (166 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 109 (66%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Cytochrome P450 2C9, Cytochrome P450 3A4, Cytochrome P450 2C19.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
vulvovaginal candidiasis	4	MONDO:0006014	EFO:0007543
tinea pedis	2	MONDO:0005984	EFO:0007512
tinea unguium	2	MONDO:0001628	MONDO:0001628
fungal infectious disease	1	MONDO:0002041	MONDO:0002041

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE2	4
PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03561701	PHASE3	COMPLETED	A Study of Oral Oteseconazole (VT-1161) for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)
NCT03562156	PHASE3	COMPLETED	A Study of Oral Oteseconazole for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)
NCT01891305	PHASE2	COMPLETED	A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Moderate - Severe Interdigital Tinea Pedis
NCT01891331	PHASE2	COMPLETED	A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection)
NCT02267356	PHASE2	COMPLETED	A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Onychomycosis of the Toenail
NCT02267382	PHASE2	COMPLETED	A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).